Heart Matters

Epizódok

• 
  The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice 14.08.2026 16p

  Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erin D. Michos, MD, MHS Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a more careful evaluation for underlying causes and risk becomes important.4 That’s why Dr. Charles Turck sits down with Dr. Erin Michos to discuss what sHTG is, why it’s so important to identify, and how we can effectively manage this condition to improve patients’ overall health and reduce complication risk. Dr. Erin Michos is a Professor of Medicine, Director of Women’s Cardiovascular Health, and Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine. References: Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2025;22:100978. doi:10.1016/j.ajpc.2025.100978 Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. doi:10.1186/s12944-021-01488-8 Sikora Kessler A, Baum SJ, Kutrieb E, et al. Rates …
• 
  Evaluating ASCVD Risk with the CPR Framework 10.08.2026 4p

  Guest: Roger Blumenthal, MD The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, joins us to explain how clinicians can combine PREVENT risk estimates with risk-enhancing factors, coronary artery calcium scoring, and shared decision-making to improve cardiovascular prevention strategies. Dr. Blumenthal is also the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.
• 
  Looking Ahead in ATTR-CM Care: Improving Diagnosis, Outcomes, and Equity 02.07.2026 3p

  Guest: Frederick Ruberg, MD What will the future of transthyretin amyloid cardiomyopathy (ATTR-CM) care look like? Dr. Frederick Ruberg joins us to share his perspective on the advances that may shape the next phase of patient care, from screening and therapeutic strategies to expanded genetic testing aimed at identifying patients earlier. He's the Chief of Cardiovascular Medicine at Boston Medical Center and Thomas J. Ryan Professor of Cardiovascular Medicine at Boston University Chobanian and Avedisian School of Medicine.
• 
  Hypertension in Women: Cardiovascular Risk Across the Lifespan 01.07.2026 18p

  Host: Shelina Ramnarine, PhD Guest: Payal Kohli, MD, FACC In women, hypertension follows a distinct biological and clinical course that evolves across reproductive and menopausal transitions, but its long-term implications remain underrecognized and undertreated. In this expert-led discussion, Dr. Shelina Ramnarine and Dr. Payal Kohli examine key considerations in managing hypertension in women and explore practical strategies to improve risk assessment and patient education. Dr. Kohli is an Associate Adjunct Professor at Johns Hopkins University and Duke University, as well as the Founder and Medical Director of Cherry Creek Heart in Aurora, Colorado. This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.
• 
  Early Recognition of ATTR-CM: Key Signs and Diagnostic Strategies 25.06.2026 3p

  Guest: Valmiki Maharaj, MD With increasing recognition and more accessible diagnostic tools, ATTR-CM can no longer be overlooked in patients with atypical heart failure presentations. Dr. Valmiki Maharaj shades insights on connecting clinical clues, confirming diagnosis efficiently, and acting earlier to meaningfully impact long-term outcomes. He's the Director of the Heart Failure Clinic, the Cardiac Amyloidosis Clinic, and the Cardiovascular Disease Fellowship Program at the University of Minnesota Medical School.
• 
  Diagnosing ATTR-CM: Recent Advances and Future Directions 25.06.2026 2p

  Guest: Ronald Witteles, MD Even with growing awareness of transthyretin amyloid cardiomyopathy (ATTR-CM), delays in diagnosis remain a significant challenge. That's why Dr. Ronald Witteles, Professor of Cardiovascular Medicine at Stanford Medicine and Co-Director of the Stanford Amyloid Center, joins us to share practical strategies for recognizing ATTR-CM, implementing the appropriate diagnostic pathway, and overcoming common testing pitfalls.
• 
  When to Suspect ATTR-CM: Clues for Earlier Diagnosis 25.06.2026 4p

  Guest: Ronald Witteles, MD What clinical clues should raise suspicion for transthyretin amyloid cardiomyopathy (ATTR-CM)? Find out as Dr. Ronald Witteles examines the cardiac and extracardiac manifestations that can help us recognize this often-overlooked disease. He's a Professor of Cardiovascular Medicine at Stanford Medicine and the Co-Director of the Stanford Amyloid Center and Multidisciplinary Sarcoidosis Program.
• 
  Understanding the Mechanisms Behind Resistant Hypertension 17.06.2026 12p

  Host: Steve Jackson, PharmD Guest: Jan Basile, MD Guest: Michael J. Bloch, MD, FAHA, FASH, FNLA When blood pressure remains uncontrolled despite treatment, adding more medications may not address the underlying cause. In this expert-led discussion, Drs. Jan Basile and Michael Bloch join Dr. Steve Jackson to examine often-overlooked drivers of hypertension, including aldosterone excess, volume overload, medication adherence, and blood pressure measurement challenges. Learn how a deeper understanding of these drivers can help us distinguish resistant hypertension from pseudo-resistance and individualize treatment decisions for our patients. Dr. Basile is a Professor in the Division of Cardiology at the Medical University of South Carolina in Charleston. Dr. Bloch is a Clinical Assistant Professor in the Department of Internal Medicine at the University of Nevada School of Medicine and the Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Institute for Heart and Vascular Health in Reno. This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.
• 
  Quality of Life Conversations in ATTR-CM Care 27.05.2026 2p

  Guest: Kevin S. Shah, MD Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience significant quality of life challenges that extend beyond cardiac symptoms, including reduced mobility, fatigue, mood changes, and loss of independence. Dr. Kevin Shah discusses practical, patient-centered strategies to identify functional limitations, support emotional well-being, engage caregivers, and align treatment goals with what matters most to these patients. Dr. Shah is an Advanced Heart Failure and Transplant Cardiologist at Long Beach Memorial Hospital, as well as an Associate Professor of Medicine at the University of California Irvine School of Medicine.
• 
  Hypertension Across Diverse Populations: Practical Strategies for Equitable Care 15.05.2026 12p

  Host: Alexandria May, PharmD, BCPS Guest: Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA Hypertension is a key modifiable cardiovascular risk factor, but its prevalence, progression, and outcomes vary significantly across patient populations. In this program, Dr. Alexandria May and Dr. Keith Ferdinand discuss how social drivers of health, geography, access to care, and comorbid conditions can influence risk and outcomes. Tune in to find out how we can better address variation in hypertension across patient groups. Dr. Ferdinand is the Gerald S. Berenson Chair in Preventive Cardiology and the Director of Preventive Cardiology at Tulane University School of Medicine in New Orleans. This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.
• 
  Cardiometabolic Considerations in Familial Chylomicronemia Syndrome 13.05.2026 13p

  Host: Steve Jackson, PharmD Guest: Robert H. Eckel, MD, FAHA, FACC, FNLA Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that can severely disrupt triglyceride metabolism and place patients at risk for life-threatening complications like acute pancreatitis. Tune in to hear Dr. Robert Eckel in conversation with Dr. Steve Jackson as they break down the key cardiometabolic risks of FCS and how emerging therapies are changing the outlook for patients living with this complex disease. Dr. Eckel is a Professor of Medicine Emeritus at the University of Colorado Anschutz Medical Campus, with appointments in endocrinology, metabolism and diabetes, and cardiology.
• 
  Advances in Sports Cardiology: Updates from ACC 2026 03.04.2026 4p

  Guest: Jeffrey Hsu, MD, PhD The field of sports cardiology has experienced remarkable growth, with new guidelines, expanding programs, and increasing recognition of cardiovascular risk in athletes. Hear from Dr. Jeffrey Hsu as he shares current and emerging approaches to risk assessment, prevention, and management of cardiac conditions in this population. Dr. Hsu is a Clinical Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, and he spoke about this topic at the 2026 American College of Cardiology (ACC) Scientific Sessions.
• 
  Supporting Patients With ATTR-CM: Preserving Function and Quality of Life 31.03.2026 2p

  Guest: Joban Vaishnav, MD For patients newly diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), it's essential to set realistic expectations and prioritize whole-person care. Dr. Joban Vaishnav, Assistant Professor of Medicine and Director of the Comprehensive Amyloidosis Center at Johns Hopkins Medicine, shares insights on guiding these patients through this diagnosis.
• 
  Counseling Patients on Disease Progression in ATTR-CM 31.03.2026 2p

  Guest: Joban Vaishnav, MD When transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, an individualized and empathetic approach to patient conversations is key. Hear from Dr. Joban Vaishnav as she shares practical strategies for addressing patient fears while clarifying what progression truly means. Dr. Vaishnav is an Assistant Professor of Medicine and Director of the Comprehensive Amyloidosis Center at Johns Hopkins Medicine in Baltimore.
• 
  AI-Driven Advances in ATTR-CM Care 27.03.2026 3p

  Guest: Frederick Ruberg, MD Artificial intelligence has rapidly advanced disease recognition in transthyretin amyloid cardiomyopathy (ATTR-CM), and its role in guiding treatment selection, predicting progression, and refining prognosis is now being explored. Discover what's next in ATTR-CM care with Dr. Frederick Ruberg, Chief of Cardiovascular Medicine at Boston Medical Center and Thomas J. Ryan Professor of Cardiovascular Medicine at Boston University Chobanian & Avedisian School of Medicine.
• 
  Redefining ATTR Treatment: Key Mechanisms and Emerging Data 23.01.2026 3p

  Guest: Ahmad Masri, MD, MS New therapeutic approaches are reshaping how we think about managing transthyretin amyloidosis (ATTR). Gain insight into the next generation of ATTR therapies as Dr. Ahmad Masri highlights evolving strategies beyond traditional stabilizers. He's an Associate Professor of Medicine in the Division of Cardiovascular Medicine at Oregon Health and Science University.
• 
  Advances in ATTR-CM: Evolving Diagnostics and Therapeutics 20.01.2026 4p

  Guest: Kevin Alexander In the past decade, significant strides have been made in diagnosing and treating patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Increased disease awareness, non-invasive diagnostic tools like scintigraphy, and AI-assisted screening have led to earlier detection and improved outcomes. Learn more with Dr. Kevin Alexander, an Assistant Professor of Cardiovascular Medicine at the Stanford University School of Medicine.
• 
  Treating ATTR-CM Early: A Shift From Reactive to Strategic Care 05.01.2026 2p

  Guest: Quan Bui, MD Quality of life in transthyretin cardiac amyloidosis (ATTR-CM) varies widely by disease stage, but early detection and treatment can make a profound difference. Hear from Dr. Quan Bui as he highlights how recent therapeutic advances have transformed symptom management, even in advanced cases. Dr. Bui is a cardiologist and Assistant Professor of Medicine at UC San Diego Health.
• 
  Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health 21.11.2025 4p

  Guest: Susan Davis Emerging research is challenging long-held assumptions about the roles of estrogen and testosterone in women’s health—particularly in the context of aging and cardiometabolic risk. Hear from Dr. Susan Davis as she reviews the evolving evidence. Dr. Davis is an endocrinologist as well as the head of the Women’s Health Research Program and a Professor of Women's Health at Monash University in Melbourne, Australia. She also spoke about this topic at the 2025 American Heart Association Scientific Sessions.
• 
  Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control 21.11.2025 4p

  A recent study explored the emerging role of KCNQ5 potassium channels in vascular smooth muscle regulation and their potential as therapeutic targets to promote vasodilation and manage blood pressure. Hear from Dr. Geoffrey Abbott as he dives into cutting-edge research using a CRISPR-generated KCNQ5 knockout rat model, revealing critical insights into adrenergic signaling, vascular reactivity, and the vascular effects of aloperine. Dr. Abbott is a Professor and Interim Chair of Physiology and Biophysics at the UC Irvine School of Medicine, and he also spoke about this topic at the 2025 American Heart Association Scientific Sessions.